Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey

Abstract

ACL without APS before kidney transplantation is an independent risk factor of eGFR decline within the first year post-transplant without over-incidence of TEs. Specific immunosuppressive therapy including mammalian target of rapamycin inhibitors should be discussed in the future.